Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
X.Y. Wang
Observed names:
Wang, Xiaoyan,
Xiaoyan Wang
Institutions:
Zhejiang Chinese Medical University,
Nanjing Chest Hospital,
Southeast University
Observed institutions:
Zhejiang Chinese Medical University,
Nanjing Chest Hospital,
CSPC Pharmaceutical Group,
Southeast University,
Nanjing Medical University
ORCID:
0000-0002-4736-216X
Observed ORCID:
0000-0002-4736-216X
OpenAlex ID:
A5088352039
Sea Buckthorn Polyphenols Alleviate High-Fat-Diet-Induced Metabolic Disorders in Mice via Reprograming Hepatic Lipid Homeostasis Owing to Directly Targeting Fatty Acid Synthase
2024
·
Luping Yuan
, Wanlin Zhang
, et al.
·
Journal of Agricultural and Food Chemistry
·
14
Abstract 6300: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers
2023
·
Mo Dan
, Xiwu Hui
, et al.
·
Cancer Research
·
7
Significance and expression of c-erBb-2, p53, and caspase-3 in breast cancer tissue in different age groups
2018
·
Z.Y. Liu
, Lei Guo
, et al.
·
European Journal of Gynaecological Oncology
·
4
1369P Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: A prospective, single-arm, phase II clinical trial
2024
·
S.C. Fang
, L.F. Yang
, et al.
·
Annals of Oncology
PDF
EP12.01-25 Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
2023
·
S. Fang
, T. Xu
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
6
Citation count:
24
H-index:
3
I10-index:
1
Year
Topic
Type